High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19

Background: Despite lopinavir/ritonavir (LPV/RTV) demonstrating in-vitro activity against SARS-CoV-2, large trials failed to show any net clinical benefit. Since SARS-CoV-2 has an EC50 of 16.4 μg/ml for LPV this could be due to inadequate dosing. Methods: COVID-19 positive patients admitted to the h...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Front Pharmacol
Autori principali: Karolyi, Mario, Omid, Sara, Pawelka, Erich, Jilma, Bernd, Stimpfl, Thomas, Schoergenhofer, Christian, Laferl, Hermann, Seitz, Tamara, Traugott, Marianna, Wenisch, Christoph, Zoufaly, Alexander
Natura: Artigo
Lingua:Inglês
Pubblicazione: Frontiers Media S.A. 2021
Soggetti:
Pharmacology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8282360/
https://ncbi.nlm.nih.gov/pubmed/34276386
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2021.704767
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi